pdufa.bio

RYZUMVI (phentolamine)

Page updated ·next FDA decision on the calendar ·Data as of Oct 21, 2026 12:50 PM ET

RYZUMVI (phentolamine) The FDA approved it on Oct 16, 2026. 2 FDA decisions on record below. Every date links its source.

IRD catalyst hub · VTRS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 2 catalyst events for this program: 0 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Oct 16, 2026 ✓ ApprovedIRDFDA decision · Oct 16, 2026 ✓ ApprovedVTRS

Questions

When is RYZUMVI (phentolamine)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for RYZUMVI (phentolamine); 2 FDA decisions are on record below.

What happened at RYZUMVI (phentolamine)'s most recent FDA decision?

On Oct 16, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has RYZUMVI (phentolamine) been approved by the FDA?

Yes. The FDA approved an application for RYZUMVI (phentolamine) on Oct 16, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.